KMID : 1036020230120030213
|
|
ÁöÁú.µ¿¸Æ°æÈÇÐȸÁö 2023 Volume.12 No. 3 p.213 ~ p.222
|
|
The Cardiovascular Effect of Tirzepatide: A Glucagon-Like Peptide-1 and Glucose-Dependent Insulinotropic Polypeptide Dual Agonist
|
|
Cho Yun-Kyung
Lee Yoo-La Jung Chang-Hee
|
|
Abstract
|
|
|
Glucagon-like peptide-1 (GLP-1) receptor agonists have been used extensively in the clinic and have an established safety profile in cardiovascular disease settings. For the treatment of peptide-secreting enteroendocrine cells, most research has focused on developing peptide multi-agonists as most of these cells are multihormonal. Among the various peptides secreted by enteroendocrine cells, the combination of GLP-1 and glucose-dependent insulinotropic polypeptide (GIP) is an attractive strategy for treating type 2 diabetes mellitus (T2DM) because both of these hormones have glucose-lowering actions. Tirzepatide, a synthetic peptide composed of 39 amino acids, functions as a dual receptor agonist of both the GIP and GLP-1 receptors. This unique mechanism of action has earned tirzepatide the nickname ¡°twincretin.¡± Tirzepatide¡¯s dual agonist activity may be the mechanism by which tirzepatide significantly reduces glycated hemoglobin levels and body weight in patients with T2DM as observed in phase 3 clinical trials. Besides its glucose-lowering and anti-obesity effects, tirzepatide has been reported to have potential cardiovascular benefits. In this review, we discuss the cardiovascular effects of tirzepatide based on the available preclinical and clinical data.
|
|
KEYWORD
|
|
Tirzepatide, GLP-1, Glucose-dependent insulinotropic peptide, Cardiovascular risk factors
|
|
FullTexts / Linksout information
|
|
|
|
Listed journal information
|
|
|